Taysha Gene Therapies Inc reports a Return on Equity (ROE) of -61.28%.

What is TSHA's dividend yield?

Taysha Gene Therapies Inc offers a dividend yield of 0.00%.

What is TSHA's Quality Score?

Our AI rates TSHA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TSHA?

Our AI Timing Score for TSHA is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TSHA belong to?

Taysha Gene Therapies Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Taysha Gene Therapies Inc (TSHA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

TSHA AI Analysis Summary

Our AI summary for TSHA: Taysha Gene Therapies Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -61.28%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 94/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TSHA

Taysha Gene Therapies Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 6.20

0.42 (7.27%) Day Change

Watchlist Portfolio Compare Chart

0.23

D/E

-61.3%

ROE

-43.2%

ROA

0.00%

Div Yield

TAYSHA GENE THERAPIES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 6.20 Price 0.42 (7.27%) Day Change	NEWS SCORE: N/A

TSHA, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	6.20
PBV / Sector	7.84 / 44,022.72
Earning Per Share	-0.48

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	16.00 M GREAT
Average 1W Daily Value	12.98 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,738.40 / 98.24
NPM Average (%) / Sector	-2,256.52 / -1,697.63
NPM Change Average (%) / Sector	4.81 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-43.24 / 185,260.96
ROA Average (%) / Sector	-65.35 / 36,684.70
ROA Change Average (%) / Sector	-17.86 / 422,221.66
ROE (%) / Sector	-61.28 / 243,762.23
ROE Average (%) / Sector	-3,574.54 / 48,758.47
ROE Change Average (%) / Sector	-35.28 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:59
Symbol	TSHA
Name	TAYSHA GENE THERAPIES INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	287.36 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,660.95 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247

Phone: 214 612 0000

Website: https://www.tayshagtx.com

Employees: 99

Sector: Healthcare >> Biotechnology

Description: Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.